In cancers, excessive stimulation of CDKs is often observed through the overexpression of cyclins (e.g., cyclin D1) in breast cancer, inactivation of cell cycle blockers, such as incorrect functioning of CDK blockers (p16INK4A), lack of response to cell cycle arrest signals, e.g., by TP53 mutations [68]. This evidence concerns the gene TP53 and cancer.